Akero Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2020 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Akero Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2020 to Q3 2024.
  • Akero Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 8.81 %, a 6.18% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 8.81 -0.58 -6.18% Sep 30, 2024
Q2 2024 8.33 -1.45 -14.8% Jun 30, 2024
Q1 2024 8.16 -4.8 -37.1% Mar 31, 2024
Q4 2023 9.16 -3.95 -30.1% Dec 31, 2023
Q3 2023 9.39 -5.84 -38.3% Sep 30, 2023
Q2 2023 9.78 -7.12 -42.1% Jun 30, 2023
Q1 2023 13 +0.35 +2.78% Mar 31, 2023
Q4 2022 13.1 +3.42 +35.3% Dec 31, 2022
Q3 2022 15.2 +7.76 +104% Sep 30, 2022
Q2 2022 16.9 +11.2 +196% Jun 30, 2022
Q1 2022 12.6 +6.99 +125% Mar 31, 2022
Q4 2021 9.69 +3.58 +58.6% Dec 31, 2021
Q3 2021 7.47 +0.93 +14.2% Sep 30, 2021
Q2 2021 5.7 -1.35 -19.1% Jun 30, 2021
Q1 2021 5.61 +0.28 +5.26% Mar 31, 2021
Q4 2020 6.11 Dec 31, 2020
Q3 2020 6.54 Sep 30, 2020
Q2 2020 7.05 Jun 30, 2020
Q1 2020 5.33 Mar 31, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.